2022 World Conference on Lung Cancer (Posters)-P2.12-01. Intratumoural Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)

P2.12-01. Intratumoural Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)

Back to course

Pdf Summary

Researchers at Yale University School of Medicine have found that the presence of conventional type 1 dendritic cells (cDC1s) within tumors can predict the response to immunotherapy in non-small cell lung cancer (NSCLC) patients. The study analyzed five cohorts of NSCLC patients who were either treated with immune checkpoint blockers or standard non-immunotherapy. The abundance of cDC1s, as well as their distribution within the tumor tissue, was measured using quantitative immunofluorescence panels. It was found that cDC1s comprised a small fraction of cells within the tumor microenvironment, with higher levels observed in KRAS-mutated lung adenocarcinomas compared to those with EGFR mutations. Increased cDC1 density within the tumor-cell compartment was associated with markers of a productive local adaptive immune response and T-cell regulation. In patients treated with immune checkpoint blockers, higher cDC1 density within the tumor-cell area was associated with a better clinical response, including durable clinical benefit and improved overall survival. No consistent association with outcomes was observed in cDC1s located in the stromal-cell compartment or in non-cDC1 subsets. The study suggests that intratumoral cDC1s can serve as a predictive marker for the response to immunotherapy in NSCLC patients. However, further research is needed to fully understand the role of cDC1s and their interactions with other immune cells in determining treatment outcomes.

Asset Subtitle

Angelo Porciuncula, United States

Meta Tag

Speaker Angelo Porciuncula, United States

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

Yale University School of Medicine

conventional type 1 dendritic cells

cDC1s

immunotherapy

non-small cell lung cancer

NSCLC

immune checkpoint blockers

tumor microenvironment

KRAS-mutated lung adenocarcinomas

EGFR mutations